Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
ProLynx
AddedFeb 15, 2024
UpdatedJun 18, 2026
ProLynx

ProLynx

Seed

ProLynx, a San Francisco-based company, innovates in controlled release of therapeutics using advanced linker technologies.

HQ
San Francisco, CA, US
Founded
2009
Overview
Compare
Fundraising
Employees
Website

ProLynx, founded in 2009 by Daniel V. Santi, M.D., Ph.D., and Gary W. Ashley, Ph.D., is a San Francisco-based company specializing in the controlled release of therapeutics. The company has developed advanced linker technologies that enable the sustained and predictable release of drugs, including peptides, proteins, and small molecules, from circulating and fixed macromolecular conjugates. ProLynx aims to overcome the limitations of current drug conjugates used for half-life extension, targeting the pharmaceutical and biotechnology markets.

Notable figures associated with ProLynx include its founders, Daniel V. Santi and Gary W. Ashley, who bring extensive expertise in medical and pharmaceutical sciences. The company has achieved significant milestones in drug delivery technology, particularly with its β-eliminative drug delivery system. This innovative approach has positioned ProLynx as a leader in the field of therapeutic release, making a substantial impact on the efficacy and predictability of drug therapies.

ProLynx - Quick Facts

When was ProLynx founded?

ProLynx was founded in 2009.

Where is ProLynx's headquarters located?

ProLynx's headquarters is located in San Francisco, CA, US.

When was ProLynx's last funding round?

ProLynx's most recent funding round was for $55.2k (USD) in August 2020.

How much has ProLynx raised to-date?

As of Aug 28, 2020, ProLynx has raised a total of $2.3M (USD).

How many employees does ProLynx have?

ProLynx has 12 employees as of Feb 5, 2024.

ProLynx - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Delivery
  • Therapeutics
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations